

icometrix's MRI measures for people with Multiple Sclerosis receive Medtech Innovation briefing from NICE

icometrix announced the recent release of a Medtech Innovation Briefing from the internationally renowned NICE for the CE markers & FDA cleared icobrain MS.


LONDON, ENGLAND, April 21, 2022 /EINPresswire.com/ -- [icometrix](https://www.icometrix.com/), the worldwide leader in digital health technology solutions for neurological conditions, announced the recent release of a Medtech Innovation [Briefing](#) (MIB) [MIB291] from the internationally renowned NICE for the CE markers and FDA cleared icobrain MRI measures in Multiple Sclerosis (MS).

In Multiple Sclerosis, software guided MRI measures of new and enlarging lesions and brain shrinkage are rapidly becoming the standard of care in MS clinical and therapeutic decision-


making. The icobrain deep learning AI solution, developed by icometrix, is the most widely adopted and best validated clinical tool for individual people with MS. The added value of icobrain compared to current practice has been acknowledged by experts in the field, leading to the first MIB for Multiple Sclerosis care being issued.

"In MS, it is crucial to detect disease activity early for best informed treatment decisions and outcomes", states Prof. Klaus Schmierer from Queen Mary University of London and Barts Health NHS Trust. "In addition to clinical scores, neurologists rely heavily on MRI to make therapeutic decisions. Hence, there is a significant need for sensitive and accurate MRI indices", he continues. "This NICE MIB is an acknowledgement of icobrain as a leading competitor in the field of AI-supported MRI analysis and, more generally, data-driven care management with


icobrain output



Color-coded segmentations in DICOM format



Concise reports with normative reference data



Prepopulated Reporting Template (PRT) in DICOM SR or encapsulated DICOM format

icobrain output includes color-coded segmentations in DICOM format, concise reports with normative reference data, and pre-populated reporting templates.



icometrix
MEASURABLY BETTER

potential to enhance the standard of care for people with MS in the UK and beyond”, Prof. Schmierer concludes.

“We are thrilled by this MIB recognition from NICE and the experts in this field”, Dr. Wim Van Hecke, founder and CEO of icometrix, comments. “We are proud to lead digital health innovation in the field of MS (and neurological conditions in general), with this first MIB in the field of MS. Being spun out of academics, science and validation are in our DNA. We all know that digital health technology is a crucial component of personalized medicine in neurology, but the importance of clinical validation cannot be underestimated”, Dr. Van Hecke concludes.

Read the NICE Medtech Innovation Briefing [MIB291]: <https://www.nice.org.uk/advice/mib291>

About icometrix

Founded in 2011, icometrix (Leuven, Belgium; Boston, USA) strives for data-driven insights and personalized patient care, supported by artificial intelligence. icometrix offers a portfolio of eight regulatory approved AI solutions to assist healthcare with various challenges; icobrain extracts data from brain MRI and CT scans for the radiological reporting and clinical management of neurological disorders such as multiple sclerosis, brain trauma, epilepsy, stroke, dementia, and Alzheimer's disease. icompanion, a digital platform, and mobile app helps people with MS and their care team to monitor clinical symptoms and treatments efficiently and objectively. icolung was one of the first available AI solutions to support clinicians responding to the rapidly evolving needs of the COVID-19 pandemic.

Today, icometrix is internationally active and integrated into more than 100 clinical practices. In addition, icometrix supports pharmaceutical companies in phase I-III and Real-World Evidence (RWE) studies through imaging and data services, and digital health strategy.

Laurent Bettens

icometrix

+32 16 36 90 00

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/569408136>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.